Technology Lead, Discovery Proteomics SRF
Contact information
Research groups
Iolanda Vendrell
Technologly Lead, Discovery Proteomics SRF
PhD
Iolanda Vendrell joined the Discovery Proteomics Facility at the University of Oxford in 2015, as a senior scientist in Biological Mass Spectrometry. She currently is the Technology Lead. She studied Biochemistry at the University of Barcelona and holds a PhD in Biochemistry (in the Neuroscience program) by the same University. Her interest in Proteomics and Mass Spectrometry started during her PhD. In 2007, she moved to the UK where she has been working in Proteomics labs in both Academia and Biotech companies. Over the years, Iolanda has developed an extensive expertise in using bottom up-proteomics for general discovery projects, biomarker discovery for clinical samples and post-translational modifications. Currently, one of her interest focuses on developing and implementing high-throughput proteomics platforms for clinical and non-clinical projects.
Recent publications
-
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex
Journal article
Damianou A. et al, (2024), Life Science Alliance, 7, e202302245 - e202302245
-
Data‐independent acquisition proteomics of cerebrospinal fluid implicates endoplasmic reticulum and inflammatory mechanisms in amyotrophic lateral sclerosis
Journal article
Dellar ER. et al, (2024), Journal of Neurochemistry, 168, 115 - 127
-
BLM and BRCA1-BARD1 coordinate complementary mechanisms of joint DNA molecule resolution
Journal article
Tsukada K. et al, (2024), Molecular Cell
-
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
Journal article
O'Brien DP. et al, (2023), Molecular & Cellular Proteomics, 22, 100609 - 100609
-
Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor Kidneys Predict 12-Month Posttransplant Outcome
Preprint
Charles PD. et al, (2023)
-
USP18 is an essential regulator of muscle cell differentiation and maturation
Journal article
Olie CS. et al, (2023), Cell Death & Disease, 14
-
Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation
Journal article
Chen Z. et al, (2022), Cell Death & Differentiation, 29, 1955 - 1969
-
High-throughput mass spectrometry maps the sepsis plasma proteome and differences in response
Preprint
Mi Y. et al, (2022)
-
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Journal article
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58
-
p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation
Journal article
Kilgas S. et al, (2021), Cell Reports, 35, 109153 - 109153
-
SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells.
Journal article
Na J. et al, (2021), Cell death & disease, 12
-
Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Journal article
Elvina Xavier M-A. et al, (2019), Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 60, 1474 - 1482
-
Metalloprotease SPRTN/DVC1 Orchestrates Replication-Coupled DNA-Protein Crosslink Repair
Journal article
Vaz B. et al, (2016), Molecular Cell, 64, 704 - 719